One tool, multiple gains: anti-CD38 therapy in antibody-mediated rejection
Clinical Kidney Journal · 12.12.2025 · 18 (Supplement_2) · ii55-ii64
DOI: 10.1093/ckj/sfaf283 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Kidney Journal, online erschienen am 11.09.2025. Verfasst von Raphaël Etiève und 7 weiteren Autor:innen. Beteiligte Einrichtung: Nephrology Department, CHU Rouen, Rouen, France. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 84 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Antibody-mediated rejection (AMR) remains a challenge in kidney transplantation, responsible for ≈20% of allograft loss. Given the limited efficiency of conventional therapies, there has been growing interest in new strategies targeting plasma cells. These include anti-CD38 monoclonal antibodies such as daratumumab, felzartamab and isatuximab. These agents, originally developed for haematologic malignancies, offer a novel strategy to target antibody secreting cells and natural killer cells, with the potential to reduce donor-specific antibodies and microvascular inflammation. Emerging clinical data suggest promising efficacy with an acceptable safety profile, sparking growing interest in their use within the transplant community. However, these effects appear transient, with a high interindividual variability, likely influenced by the heterogeneity of B cell populations after establishment of an allo-immune response. Of note, these therapeutics also affect B and T regulatory cells, raising important questions about immune balance with the risk of T cell–mediated rejection. This review synthesizes the current understanding of AMR, presents the Banff 2022 diagnostic frameworks updates and critically appraises the exciting potential and limitations of anti-CD38 therapies in AMR. As the transplant community shifts toward precision immunotherapy, anti-CD38 agents may help reshape future treatment paradigms in kidney transplantation—provided their use is guided by mechanistic insights and rigorous clinical evaluation.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Nephrology Department, CHU Rouen, Rouen, France.
- Immunology Department, U1234, Univ Rouen Normandy, CIC-CRB 1404, CHU Rouen, Rouen, France.
- Nephrology Department, U1234, Univ Rouen Normandy, CIC-CRB 1404, CHU Rouen, Rouen, France.
ORCID-Profile: Margaux Van Wynsberghe, Tristan de Nattes
Zitieren
APA
Etiève, R., Van Wynsberghe, M., Grangé, S., Laurent, C., Lemoine, M., Candon, S., Bertrand, D., & de Nattes, T. (2025). One tool, multiple gains: anti-CD38 therapy in antibody-mediated rejection. Clinical Kidney Journal, 18(Supplement_2), ii55-ii64. https://doi.org/10.1093/ckj/sfaf283
Vancouver
Etiève R, Van Wynsberghe M, Grangé S, Laurent C, Lemoine M, Candon S, et al. One tool, multiple gains: anti-CD38 therapy in antibody-mediated rejection. Clinical Kidney Journal. 2025;18(Supplement_2):ii55-ii64. doi:10.1093/ckj/sfaf283
BibTeX
@article{Etive2025,
author = {Etiève, Raphaël and Van Wynsberghe, Margaux and Grangé, Steven and Laurent, Charlotte and Lemoine, Mathilde and Candon, Sophie and Bertrand, Dominique and de Nattes, Tristan},
title = {One tool, multiple gains: anti-CD38 therapy in antibody-mediated rejection},
journal = {Clinical Kidney Journal},
year = {2025},
volume = {18},
number = {Supplement_2},
pages = {ii55--ii64},
doi = {10.1093/ckj/sfaf283}
}
EUVIMED